PDCD1 and neoplasm: Nivolumab disrupts PD-1 and PD-1 ligand 1/2 (PD-L1/2) interaction, which plays a crucial role in cancer immune tolerance, thus restoring the antitumour activity of tumour-specific T-cells [11].